Tempus AI, Inc. Class A TEM

CHICAGO, October 01, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid.

Cathie Wood just dumped one of this year's biggest AI winners to load up on a stock that has barely moved, and the reasoning behind that swap reveals a lot about where she thinks the real opportunity still sits.

Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's therapeutic mRNA cancer vaccine programs, including the Company's personalized vaccine program for pediatric brain cancer patients as well as the Company's off-the-shelf precision therapy vaccines for a range of solid tumor cancers.

CHICAGO, September 28, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR).

Goldman Sachs’ Neutral initiation of Tempus AI, Inc. (NASDAQ:TEM) on September 21 puts the company’s fastest-growing businesses under different tests: diagnostics offers visible near-term growth, while the data and applications segment faces renewal risk as several major contracts approach extensions over the next two years. The timing is notable because Tempus AI, Inc. (NASDAQ:TEM) announced […]

CHICAGO, September 21, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA Foundation Model.

On September 9, Tempus AI (NASDAQ:TEM) said ARPA-H, a US health research agency, picked it to build an AI that treats heart failure patients without a clinician stepping in. The award is worth up to $9.5 million, which is small change for a company booking hundreds of millions in quarterly sales. But the dollars are […]

Tempus AI (TEM) has put a new data project at the center of the story. The business plans a research platform built on 100,000 whole genomes linked to long term clinical records. Tempus AI’s new whole genome project arrives after a sharp run in the shares, with a 90 day share price return of 62.68% and a 7 day gain of 31.91%. However, the 1 year total shareholder return of an 11.79% decline shows the longer term picture has been more mixed despite the current momentum around the US$77.84...

Earlier this month, Tempus AI announced a multi‑year initiative to build a research platform of 100,000 whole genomes linked to longitudinal clinical, imaging, pathology and outcome data, with plans to eventually scale toward one million genomes and offer broad access via its Tempus Lens environment by mid‑2027. This move extends Tempus AI beyond targeted panels into whole‑genome sequencing, creating a model‑ready, multimodal dataset specifically tailored for AI‑driven disease and drug...

Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-world clinical and imaging records. Management targets scaling the platform to one million whole genomes tied to patient outcomes for use in drug development and personalized care. This new whole-genome sequencing and clinical data platform comes against a...

Cathie Wood's ARK Invest funds made a broad move out of crypto-linked assets during the week, led by the sale of more than 1.5 million shares of the ARK 21Shares Bitcoin ETF.

Clarity on how much revenue Tempus AI will bring in through Medicare reimbursements for two of its cancer screenings appeased investors this week as shares surged Thursday. Tempus stock added 15% Thursday as part of a 36% advance over the last five sessions. in which Tempus is the third-largest position behind Tesla and SpaceX rose 4.3%.